|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The in vivo study was carried out for the evaluation of tumor incidence, pro-inflammatory cytokines such as TNF-α and IL-1α, lipid peroxidation values, glutathione content and catalase activity in mice.
|
30742987 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
IL-1α is closely related to the development and metastasis of cancer, and its polymorphisms have been reported affecting the susceptibility of malignancy tumors, yet the conclusions are controversial.
|
31359795 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Single-Cell Analysis of Multiple Steps of Dynamic NF-κB Regulation in Interleukin-1α-Triggered Tumor Cells Using Proximity Ligation Assays.
|
31426445 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data reveal the association between genetic polymorphisms of IL-1 and BC susceptibility in the Chinese Han population and indicates that IL-1 polymorphisms are closely associated with tumor markers and IL-1β protein expression in BC patients.
|
31297985 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-37 is a cytokine of IL-1 family that plays an important role in innate immunity and inflammation, and has been studied as a tumor suppressor in many cancers.
|
31410060 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-1 receptor type 2 (IL1R2) is a decoy receptor for IL-1 cytokines and involved in host inflammatory and immune progression which could lead to the lesion and neoplasia of cervix.
|
30460760 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Given the role of IL-1 signaling in anti-tumor immune response, we hypothesized that increases in IL-1α levels would enhance tumor response to cetuximab.
|
30890189 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, leukocyte tumor infiltration and inflammation mediators showed increased cytotoxic T cells and decreased TGFβ1 expression by the HOO diet, while the HCO one increased arginase expression and IL-1α plasma levels.
|
30572269 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings indicate that tumor released IL-1α and IL-1β and ASC are key regulators of TSLP secretion by CAFs and their targeting should ultimately dampen Th2 inflammation and improve overall survival in pancreatic cancer.
|
30760333 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor/stromal IL1B and IL1 receptor 1 (IL1R1) expression was assessed in patient samples and effects of the IL1R antagonist, Anakinra, or the IL1B antibody canakinumab on tumor growth and spontaneous metastasis were measured in a humanized mouse model of breast cancer bone metastasis.
|
30670488 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When IL-1 signaling was blocked by recombinant IL-1 receptor antagonist, liver tumor formation and M2-type macrophages were reduced, suggesting that IL-1 signaling contributes to M2 polarization and tumor growth in NAFLD.
|
31044438 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pharmacological inhibition of PGE2 biosynthesis in EGCs or IL-1 knockdown in tumor epithelial cells prevented EGC acquisition of a pro-tumorigenic phenotype.
|
31662289 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, NF-ĸB was persistently activated by IL-1α-feedback loop, making HA abundance in tumor microenvironment after radiation.
|
29559744 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of IL-1α delayed growth of TAMC-induced tumors.
|
29502208 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-derived interleukin 1α (IL-1α), acting on infiltrating myeloid cells, induced the expression of a critical tumor survival factor, the cytokine TSLP.
|
29556001 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro experiments showed that stimulation with tumor cell-derived IL-1 and TNF-α increased L-PGDS mRNA expression and its product prostaglandin D<sub>2</sub> (PGD<sub>2</sub> ) in human normal ECs.
|
29124765 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In kind, IL-1 and ERα show inverse accumulation in BCa patient tumors and IL-1 is implicated in BCa progression.
|
30324661 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-1 (IL-1) is a pro-inflammatory as well as an immunostimulatory cytokine that is abundant in the tumor microenvironment.
|
28606052 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was a positive correlation between IL-1α, which was upregulated during hypoxia, and tumor stage, lymph node metastasis and resistance to cisplatin in GC.
|
28608600 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we provide an overview of the current understanding of the role of the best-validated cytokines involved in tumor progression, IL-1, IL-4 and IL-6; in addition to IL-2 cytokines family, which is known to promote tumor eradication by immune cells.
|
28927416 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Relevant to ongoing clinical trials in breast cancer, we demonstrate here that the IL-1 receptor antagonist anakinra abrogates IL-22 production and reduces tumor growth in a murine breast cancer model.
|
29150554 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have shown that in the tumor microenvironment, the IL-1 agonistic molecules act different as a result of their local amounts and their compartmentalization within the producing cells.
|
28522598 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher level of reactive oxygen species (ROS) in leukocytes and the elevation of proinflammatory plasma cytokines IL-1 and IL-2 may contribute to the observed reduction in tumor development.
|
29550799 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that targeting the inflammasome/IL-1 pathway in tumor microenvironments may provide a novel approach for the treatment of cancer.
|
27786298 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that IL-1a rs3783553 polymorphism may modulate the risk of SCCOP recurrence in patients, particularly for patients with HPV16-positive tumors.
|
27121322 |
2016 |